Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 20.76 USD -0.1% Market Closed
Market Cap: 496m USD
Have any thoughts about
Cartesian Therapeutics Inc?
Write Note

Cartesian Therapeutics Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cartesian Therapeutics Inc
Interest Income Expense Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Cartesian Therapeutics Inc
NASDAQ:RNAC
Interest Income Expense
-$153.2m
CAGR 3-Years
-296%
CAGR 5-Years
-211%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2B
CAGR 3-Years
7%
CAGR 5-Years
-9%
CAGR 10-Years
-13%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$948m
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.4B
CAGR 3-Years
-34%
CAGR 5-Years
-29%
CAGR 10-Years
-15%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$595.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$990m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Cartesian Therapeutics Inc's Interest Income Expense?
Interest Income Expense
-153.2m USD

Based on the financial report for Jun 30, 2024, Cartesian Therapeutics Inc's Interest Income Expense amounts to -153.2m USD.

What is Cartesian Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-211%

The average annual Interest Income Expense growth rates for Cartesian Therapeutics Inc have been -296% over the past three years , -211% over the past five years .

Back to Top